Literature DB >> 16890224

Specific receptor subtype mediation of LPA-induced dual effects in cardiac fibroblasts.

Jinghai Chen1, Yu Han, Weiquan Zhu, Rui Ma, Bianmei Han, Xiangfeng Cong, Shengshou Hu, Xi Chen.   

Abstract

Lysophosphatidic acid (LPA) is a phospholipid messenger with diverse effects mediated via receptors LPA1, LPA2 and LPA3. Our previous study revealed that serum LPA level is elevated after myocardial infarction (MI). However, very little is known about the effects of LPA on cardiac fibroblasts (CFs) that play a crucial role in left ventricular remodeling after MI. Here we demonstrated that LPA dose-dependently induced proliferation and collagen synthesis with the maximum stimulation at 10 microM that was preferentially mediated by LPA3. LPA also dose-dependently induced apoptotic cell death, as estimated by MTT assay, hoechst staining, TUNEL and flow cytometric analysis, with an IC(50) of 50 microM. Moreover, apoptotic cell death may involve mitochondrial dysfunction and activation of caspase-3. Apoptosis induced by LPA might be mediated by LPA1. These data suggest that LPA exerts dual proliferative and proapoptotic actions mediated by specific LPA receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890224     DOI: 10.1016/j.febslet.2006.07.061

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Developmental changes in lysophospholipid receptor expression in rodent heart from near-term fetus to adult.

Authors:  Fang Wang; Jianfeng Hou; Bianmei Han; Yu Nie; Xiangfeng Cong; Shengshou Hu; Xi Chen
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

2.  Lysophosphatidic acid stimulates epidermal growth factor-family ectodomain shedding and paracrine signaling from human lung fibroblasts.

Authors:  Tetsuya Shiomi; Francis Boudreault; Nurcicek Padem; Shigeki Higashiyama; Jeffrey M Drazen; Daniel J Tschumperlin
Journal:  Wound Repair Regen       Date:  2011 Mar-Apr       Impact factor: 3.617

3.  Gαi2 signaling: friend or foe in cardiac injury and heart failure?

Authors:  Kuljeet Kaur; Sergio Parra; Rong Chen; Raelene A Charbeneau; Susan M Wade; Patrick Y Jay; Richard R Neubig
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-03-14       Impact factor: 3.000

4.  Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model.

Authors:  Anna Axelsson Raja; Hiroko Wakimoto; Daniel M DeLaughter; Daniel Reichart; Joshua Gorham; David A Conner; Mingyue Lun; Clemens K Probst; Norihiko Sakai; Rachel S Knipe; Sydney B Montesi; Barry Shea; Leonard P Adam; Leslie A Leinwand; William Wan; Esther Sue Choi; Eric L Lindberg; Giannino Patone; Michela Noseda; Norbert Hübner; Christine E Seidman; Andrew M Tager; J G Seidman; Carolyn Y Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-05       Impact factor: 12.779

5.  Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Authors:  Gyöngyi N Kiss; James I Fells; Renuka Gupte; Sue-Chin Lee; Jianxiong Liu; Nóra Nusser; Keng G Lim; Ramesh M Ray; Fang-Tsyr Lin; Abby L Parrill; Balázs Sümegi; Duane D Miller; Gabor Tigyi
Journal:  Mol Pharmacol       Date:  2012-09-11       Impact factor: 4.436

6.  LPA-induced mutually exclusive subcellular localization of active RhoA and Arp2 mRNA revealed by sequential FRET and FISH.

Authors:  Lisa A Mingle; Ghislain Bonamy; Margarida Barroso; Guoning Liao; Gang Liu
Journal:  Histochem Cell Biol       Date:  2009-04-14       Impact factor: 4.304

7.  GRP78 enhances the glutamine metabolism to support cell survival from glucose deficiency by modulating the β-catenin signaling.

Authors:  Zongwei Li; Yingying Wang; Haili Wu; Lichao Zhang; Peng Yang; Zhuoyu Li
Journal:  Oncotarget       Date:  2014-07-30

8.  Acetylation modification regulates GRP78 secretion in colon cancer cells.

Authors:  Zongwei Li; Ming Zhuang; Lichao Zhang; Xingnan Zheng; Peng Yang; Zhuoyu Li
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.